In contrast to AI-driven drug discovery companies like Xaira, Recursion, or DeepMind spinout Isomorphic Labs, which focus on ...

Addition of XenoSTART's patient-derived tumor models expands number of models available on Scientist.com's Tumor Model Finder to over 10,000.

Medpace beats Q2 2025 earnings, raises FY guidance, showcasing strong biotech demand. Click here to read an analysis of MEDP ...

M42 is already the largest health care group in the Middle East and serves some 15 million patients worldwide with operations in 27 countries. Its revenues have grown five times in the past seven ...

Or, in the midst of an emotionally fraught conversation with a friend or family member, a text might read strangely. Is the ...

The Upper Guadalupe River Authority had a $3 million reserve, but cut taxes rather than replacing an outdated flood alert ...

N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and ...

The company raised its full-year 2025 guidance for revenue, net income, and earnings per share. These 10 stocks could mint the next wave of millionaires › Medpace (NASDAQ:MEDP), a clinical contract ...

Looking ahead to 2024, Insider has rounded up 24 of the most interesting, inspiring and innovative businesses. These ...

In times of geopolitical turmoil, leaders can build transformational capacity by balancing urgent crises with long-term ...

The global companion diagnostics market is set to surge from USD 7.03 Billion in 2024 to USD 22.83 Billion by 2034, driven by rising cancer prevalenc ...

Why local biotech firm BioAnalysis is feeling right at home in Kensington, Philly’s most beleaguered neighborhood ...